|
|
|
Mainz Biomed N v (NASDAQ: MYNZ) |
|
Mainz Biomed N v
MYNZ's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Mainz Biomed N V growth rates, revenue grew
by 69 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 313
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Mainz Biomed N V net loss decreased from $-26 millions, to $-26 millions in IV. Quarter 2023,
• More on MYNZ's Growth
|
|
Mainz Biomed N V
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.11 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 2.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
• More on MYNZ's Valuation
|
|
|
|
|
Mainz Biomed N V
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.11 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 2.19.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
Mainz Biomed N V Price to Book Ratio is at 0.6 lower than Industry Avg. of 1351.85. and higher than S&P 500 Avg. of 0.01
• More on MYNZ's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
